NasdaqGS:ARWRBiotechs
Dual Gene Silencing Data Will Impact Arrowhead Pharmaceuticals Stock Investors
Arrowhead Pharmaceuticals reported interim Phase 1/2a data for ARO-DIMER-PA, showing single-dose dual gene silencing of PCSK9 by 72% and APOC3 by 88%, with no drug related serious adverse events in adults with mixed hyperlipidemia.
The result that one RNAi molecule achieved deep and durable silencing of two cardiometabolic genes positions ARO-DIMER-PA as a differentiated asset in Arrowhead Pharmaceuticals' broader RNA interference pipeline.
This development may influence how investors view...